Companies: 10,795·Total market cap: $144.5T
INNOCAN PHARMA Corp

INNOCAN PHARMA Corp

INNPFOTCHealthcare● Active
$2.40
$-0.05(-2.04%)
Market Cap$10797048
P/E Ratio
52W High$14.26
52W Low$2.354

INNOCAN PHARMA Corp (INNPF) Revenue

Annual & quarterly revenue history · segment & region breakdown

INNPF · revenue · updated Jun 9, 2026

Core revenue metrics

INNOCAN PHARMA Corp trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
11 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · INNOCAN PHARMA Corp SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
INNPF revenue by year · INNPF revenue history · INNPF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income INNOCAN PHARMA Corp receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

INNOCAN PHARMA Corp reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from INNOCAN PHARMA Corp's 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

INNPF revenue · 4 questions

INNPF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

INNPF revenueINNPF annual revenuewhat is INNPF revenueINNPF TTM revenue

Source: FMP · INNOCAN PHARMA Corp SEC filings · GAAP · INNOCAN PHARMA Corp SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026